4 results match your criteria: "Massachusetts. Electronic address: bnguyen2@Tuftsmedicalcenter.org.[Affiliation]"
Higher risk of melanoma-related deaths for patients residing in rural counties: A Surveillance, Epidemiology, and End Results Program study.
J Am Acad Dermatol
June 2024
Department of Dermatology, Tufts Medical Center, Boston, Massachusetts. Electronic address:
Limited commercialization of artificial intelligence technology in the diagnosis of pigmented lesions despite explosive growth in published programs.
J Am Acad Dermatol
December 2023
Department of Dermatology, Tufts Medical Center, Boston, Massachusetts. Electronic address:
Geographic variability of pricing and insurance coverage of topical actinic keratosis therapy: A survey-based study.
J Am Acad Dermatol
March 2023
Department of Dermatology, Tufts Medical Center, Boston, Massachusetts; Tufts University School of Medicine, Boston, Massachusetts. Electronic address:
A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance.
J Am Acad Dermatol
August 2015
Department of Dermatology, Tufts Medical Center, Tufts University School of Medicine, Boston, Massachusetts. Electronic address:
Background: The reported efficacy of imiquimod for lentigo maligna varies widely, without consensus on tumor or treatment factors that can impact tumor clearance.
Objective: We sought to provide a more precise estimate of clearance rates in patients with lentigo maligna who are treated with imiquimod and to analyze factors that can impact tumor clearance.
Methods: We performed a literature search for biopsy-proven lentigo maligna treated with imiquimod monotherapy, linked treatment and outcome data to individual tumors, calculated histologic and clinical clearance rates with 95% confidence intervals (CIs), and analyzed the impact of tumor and treatment factors on tumor clearance using logistic regression.